

Nicola L Coley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3195780/publications.pdf>

Version: 2024-02-01

81
papers

3,600
citations

212478

28
h-index

162838

57
g-index

83
all docs

83
docs citations

83
times ranked

4987
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Cutoff for the Chair Stand Test as a Screening for Mobility Impairment in the Context of the Integrated Care for Older People Program. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 104-110.	1.7	4
2	Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials. <i>Alzheimer's and Dementia</i> , 2022, 18, 676-687.	0.4	8
3	The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). <i>Alzheimer's and Dementia</i> , 2022, 18, 1325-1334.	0.4	24
4	Physical activity, body mass index, and blood progranulin in older adults: cross-sectional associations in the MAPT study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, , .	1.7	1
5	Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2140-2150.	0.4	17
6	Plasma MCP-1 and changes on cognitive function in community-dwelling older adults. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 5.	3.0	10
7	One-Year Impact of COVID-19 Lockdown-Related Factors on Cardiovascular Risk and Mental Health: A Population-Based Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1684.	1.2	6
8	Factors Predicting Engagement of Older Adults With a Coach-Supported eHealth Intervention Promoting Lifestyle Change and Associations Between Engagement and Changes in Cardiovascular and Dementia Risk: Secondary Analysis of an 18-Month Multinational Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e32006.	2.1	22
9	Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults. <i>GeroScience</i> , 2022, 44, 1489-1503.	2.1	3
10	Response to "Upping the dose of dementia risk reduction". <i>Alzheimer's and Dementia</i> , 2022, , .	0.4	0
11	Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients. <i>Drugs and Aging</i> , 2022, 39, 367-375.	1.3	2
12	Biological and Neuroimaging Markers as Predictors of 5-Year Incident Frailty in Older Adults: A Secondary Analysis of the MAPT Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e361-e369.	1.7	11
13	Kidney Function and Cognitive Decline in Older Adults: Examining the Role of Neurodegeneration. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 651-659.	1.3	12
14	Lockdown-related factors associated with the worsening of cardiovascular risk and anxiety or depression during the COVID-19 pandemic. <i>Preventive Medicine Reports</i> , 2021, 21, 101300.	0.8	17
15	Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults: The MAPT Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1382-1390.	1.7	20
16	Prevention of dementia using mobile phone applications (PRODEMOS): protocol for an international randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e049762.	0.8	18
17	Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. <i>Scientific Reports</i> , 2021, 11, 13394.	1.6	22
18	Disparities in the participation and adherence of older adults in lifestyle-based multidomain dementia prevention and the motivational role of perceived disease risk and intervention benefits: an observational ancillary study to a randomised controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 157.	3.0	18

#	ARTICLE	IF	CITATIONS
19	Physical activity and sedentary time in a multimodal lifestyle intervention in prodromal Alzheimer's disease: The MIND ^{AD} _{MINI} pilot trial. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
20	Engagement with a preventive eHealth intervention in older adults (the HATICE trial): Predictive factors and associations with dementia and cardiovascular risk. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
21	Design and Development of a Mobile Health (mHealth) Platform for Dementia Prevention in the Prevention of Dementia by Mobile Phone Applications (PRODEMOS) Project. <i>Frontiers in Neurology</i> , 2021, 12, 733878.	1.1	5
22	Plasma A β 2 and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 128.	3.0	20
23	Dementia risk scores as surrogate outcomes for lifestyle-based multidomain prevention trials: rationale, preliminary evidence and challenges. <i>Alzheimer's and Dementia</i> , 2020, 16, 1674-1685.	0.4	18
24	Meal-related difficulties and weight loss in older people: Longitudinal data from MAPT study. <i>Clinical Nutrition</i> , 2020, 39, 3483-3488.	2.3	3
25	Pooling individual participant data from randomized controlled trials: Exploring potential loss of information. <i>PLoS ONE</i> , 2020, 15, e0232970.	1.1	2
26	Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. <i>BMC Geriatrics</i> , 2020, 20, 99.	1.1	28
27	Attitudes of at-risk older adults about prevention of cardiovascular disease and dementia using eHealth: a qualitative study in a European context. <i>BMJ Open</i> , 2020, 10, e037050.	0.8	4
28	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3-year analysis of the multidomain Alzheimer preventive trial (MAPT) study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 71-99.	1.1	18
29	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. <i>Alzheimer's and Dementia</i> , 2019, 15, 729-741.	0.4	68
30	Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. <i>The Lancet Digital Health</i> , 2019, 1, e424-e434.	5.9	83
31	Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 843-849.e5.	1.2	28
32	TRAJECTORY OF THE MAPT-PACC-PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE IN THE PLACEBO GROUP OF A RANDOMIZED CONTROL TRIAL: RESULTS FROM THE MAPT STUDY: LESSONS FOR FURTHER TRIALS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2018, 5, 1-5.	1.5	10
33	Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 649-663.	1.2	36
34	Effects of a 3-Year Multi-Domain Intervention with or without Omega-3 Supplementation on Cognitive Functions in Older Subjects with Increased CAIDE Dementia Scores. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 71-78.	1.2	49
35	Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?. <i>Journal of Nutrition, Health and Aging</i> , 2018, 22, 982-988.	1.5	13
36	Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 1505-1513.	1.3	20

#	ARTICLE	IF	CITATIONS
37	Effect of dementia on receipt of influenza vaccine: a cohort study in French older adults using administrative data: 2007-2012. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 471-480.	1.0	5
38	Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 377-389.	4.9	576
39	Cognitive changes with omega-3 polyunsaturated fatty acids in non-demented older adults with low omega-3 index. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 988-993.	1.5	45
40	Cross-sectional associations of total plasma homocysteine with cortical β -amyloid independently and as a function of omega 3 polyunsaturated fatty acid status in older adults at risk of dementia. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 1075-1080.	1.5	14
41	Lessons from the Multidomain Alzheimer Preventive Trial - Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 586.	4.9	2
42	[O3-01-06]: ADHERENCE TO MULTIDOMAIN INTERVENTIONS FOR THE PREVENTION OF ALZHEIMER'S DISEASE: DATA FROM THE MAPT AND FINGER TRIALS. <i>Alzheimer's and Dementia</i> , 2017, 13, P895.	0.4	1
43	[P3-578]: ACCEPTANCE: A MIXED METHODS STUDY OF FACILITATORS AND BARRIERS TO PARTICIPATION IN AN INTERNET-BASED MULTIDOMAIN TRIAL FOR THE PREVENTION OF CARDIOVASCULAR DISEASE AND COGNITIVE DECLINE IN OLDER EUROPEAN ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1201.	0.4	2
44	Cross-sectional Associations of Fatigue with Cerebral β -Amyloid in Older Adults at Risk of Dementia. <i>Frontiers in Medicine</i> , 2017, 4, 173.	1.2	9
45	Improving data sharing in research with context-free encoded missing data. <i>PLoS ONE</i> , 2017, 12, e0182362.	1.1	3
46	Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. <i>BMJ Open</i> , 2016, 6, e010806.	0.8	75
47	Evaluating the clinical relevance of a cognitive composite outcome measure: An analysis of 1414 participants from the 5-year GuidAge Alzheimer's prevention trial. <i>Alzheimer's and Dementia</i> , 2016, 12, 1216-1225.	0.4	23
48	Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives. <i>Alzheimer's and Dementia</i> , 2016, 12, 427-437.	0.4	31
49	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	1.2	28
50	A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort. <i>Journal of the American Medical Directors Association</i> , 2015, 16, 1104.e1-1104.e7.	1.2	12
51	Nutrition and Cognition in Aging Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 453-464.	1.0	22
52	Prevention Studies in Alzheimer's Disease: Progress Towards the Development of New Therapeutics. <i>CNS Drugs</i> , 2015, 29, 519-528.	2.7	7
53	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. <i>Lancet Neurology</i> , The, 2015, 14, 926-944.	4.9	227
54	Understanding the Complexities of Functional Ability in Alzheimer's Disease: More Than Just Basic and Instrumental Factors. <i>Current Alzheimer Research</i> , 2014, 11, 357-366.	0.7	20

#	ARTICLE	IF	CITATIONS
55	How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force. <i>Journal of Nutrition, Health and Aging</i> , 2013, 17, 619-623.	1.5	11
56	Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2013, 9, S45-55.	0.4	96
57	Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer's Disease Patients: Evidence for a Role of Dementia Severity. <i>Current Alzheimer Research</i> , 2012, 9, 1106-1116.	0.7	32
58	Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 851-859.	4.9	331
59	Methodological challenges in designing dementia prevention trials – The European Dementia Prevention Initiative (EDPI). <i>Journal of the Neurological Sciences</i> , 2012, 322, 64-70.	0.3	96
60	Improving Care of Older Adults With Dementia: Description of 6299 Hospitalizations over 11 Years in a Special Acute Care Unit. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 486.e1-486.e6.	1.2	28
61	Representations and practices of prevention in elderly populations: Investigating acceptance to participate in and adherence to an intervention study for the prevention of Alzheimer's disease (accept) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> 352-354.	1.5	10
62	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.	2.8	119
63	Suitability of the Clinical Dementia Rating Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. <i>Alzheimer's and Dementia</i> , 2011, 7, 602.	0.4	79
64	Long-term progression of Alzheimer's disease in patients under antidementia drugs. <i>Alzheimer's and Dementia</i> , 2011, 7, 579-592.	0.4	60
65	Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study. <i>Social Science and Medicine</i> , 2011, 72, 1310-1316.	1.8	31
66	How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?. <i>Current Alzheimer Research</i> , 2011, 8, 421-433.	0.7	26
67	Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). <i>BMJ: British Medical Journal</i> , 2010, 340, c2466-c2466.	2.4	48
68	Predictive Factors of Discontinuation and Switch of Cholinesterase Inhibitors in Community-Dwelling Patients with Alzheimer's Disease. <i>CNS Drugs</i> , 2010, 24, 431-442.	2.7	29
69	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 235-270.	1.2	42
70	Cardiovascular Disease Risk Factors and Progression of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 27, 240-246.	0.7	26
71	Biomarkers in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 119-124.	1.8	26
72	Determinants of students' attitudes towards peers with disabilities. <i>Developmental Medicine and Child Neurology</i> , 2009, 51, 473-479.	1.1	123

#	ARTICLE	IF	CITATIONS
73	Memory complaints to the general practitioner: Data from the GuidAge study. <i>Journal of Nutrition, Health and Aging</i> , 2008, 12, S66-S72.	1.5	34
74	Measuring children's attitudes towards peers with disabilities: a review of instruments. <i>Developmental Medicine and Child Neurology</i> , 2008, 50, 182-189.	1.1	68
75	Endpoints for trials in Alzheimer's disease: a European task force consensus. <i>Lancet Neurology</i> , The, 2008, 7, 436-450.	4.9	146
76	Dementia Prevention: Methodological Explanations for Inconsistent Results. <i>Epidemiologic Reviews</i> , 2008, 30, 35-66.	1.3	145
77	Predictive Factors of Attrition in a Cohort of Alzheimer Disease Patients. <i>Neuroepidemiology</i> , 2008, 31, 69-79.	1.1	47
78	Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with <i>Burkholderia cepacia</i> complex: results from two French centres. <i>Thorax</i> , 2008, 63, 732-737.	2.7	101
79	GuidAge Study: A 5-Year Double Blind, Randomised Trial of EGb 761 for the Prevention of Alzheimers Disease in Elderly Subjects with Memory Complaints. I. Rationale, Design and Baseline Data. <i>Current Alzheimer Research</i> , 2008, 5, 406-415.	0.7	47
80	Disease Modifying Trials in Alzheimer's Disease: Perspectives for the Future. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 289-301.	1.2	15
81	Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. <i>International Journal of Antimicrobial Agents</i> , 2006, 28, 226-230.	1.1	62